Impact of Cytogenetic Response to Therapy on Long‐Term Survival in Acute Myeloid Leukemia
Authors:
Open Access
- 11 July 2025
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (9) , 1577-1589
Abstract
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event‐free survival (EFS) in AML. Among 973 adult AML patients treated at Cleveland Clinic (5/2017–9/2023), 563 patients had baseline cytogenetic data and post‐treatment response assessment available. Based on baseline and response cytogenetic status, patients were categorized into: normal to normal (NL‐Cy to NL‐Cy, n = 221, 39%), normal or abnormal to gain (NL/Abnl‐Cy to Gain‐Cy, n = 46, 8.2%), abnormal to persistent (Abnl‐Cy to Persistent‐Cy, n = 81, 14%), abnormal to partial response (Abnl‐Cy to Partial‐Cy, n = 20, 3.6%), and abnormal to complete response (Abnl‐Cy to NL‐Cy, n = 195, 35%). Landmark analysis was used to account for post‐treatment assessments. The cohort had a median age of 62 years (interquartile range: 52–69), 256 females (45%), 90% were White, and median follow‐up of 45.8 months (range: 0.73–191.3). The median OS and hazard ratios (HRs) from multivariable regression analysis were as follows: NL‐Cy to NL‐Cy: 37 months (95% CI: 27–91), HR = reference; NL/Abnl‐Cy to Gain‐Cy: 14 months (95% CI: 8.6–30), HR = 1.5 (95% CI: 0.99–2.39); Abnl‐Cy to Persistent‐Cy: 13 months (95% CI: 12–18), HR = 1.61 (95% CI: 1.13–2.31); Abnl‐Cy to Partial‐Cy: 25 months (95% CI: 14‐NC), HR = 0.76 (95% CI: 0.39–1.49); and Abnl‐Cy to NL‐Cy: 27 months (95% CI: 19–101), HR = 1.25 (95% CI: 0.93–1.68) (p = 0.038). Achieving cytogenetic remission, complete or partial, was associated with better survival outcomes. These findings highlight the importance of monitoring cytogenetic responses to inform treatment decisions and support integrating cytogenetic response into risk‐adapted, personalized AML management strategies.Keywords
This publication has 20 references indexed in Scilit:
- Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid LeukemiaEuropean Journal of Haematology, 2024
- Detection of complex chromosome rearrangements using optical genome mappingGene, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Prediction of survival with intensive chemotherapy in acute myeloid leukemiaAmerican Journal of Hematology, 2022
- European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall responseBlood Cancer Journal, 2022
- Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemiaNature Communications, 2021
- Optical genome mapping enables constitutional chromosomal aberration detectionThe American Journal of Human Genetics, 2021
- Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid CancersNew England Journal of Medicine, 2021
- Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete RemissionTransplantation and Cellular Therapy, 2013
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009